Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.

Zalcman G, Madroszyk A, Guenzi E, Dayen C, Molinier O, Egenod T, Poté N, Debieuvre D, Beaucaire-Danel S, Dixmier A, Pichon E, Galland-Girodet S, Giroux-Leprieur E, Cloarec N, Cadranel J, Otto J, Romand P, Favier L, Martinez S, Mascaux C, Odier L, Cortot A, Audigier-Valette C, Langlais A, Amour E, Morin F, Antoine M, Gounant V, Westeel V, Toffart AC

Open source

DOI: 10.1016/j.jtho.2026.103609
Published: 2026 Jun
Container: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2026.103609,
  title = {Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.},
  author = {Zalcman G and Madroszyk A and Guenzi E and Dayen C and Molinier O and Egenod T and Poté N and Debieuvre D and Beaucaire-Danel S and Dixmier A and Pichon E and Galland-Girodet S and Giroux-Leprieur E and Cloarec N and Cadranel J and Otto J and Romand P and Favier L and Martinez S and Mascaux C and Odier L and Cortot A and Audigier-Valette C and Langlais A and Amour E and Morin F and Antoine M and Gounant V and Westeel V and Toffart AC},
  year = {2026},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2026.103609},
  url = {https://doi.org/10.1016/j.jtho.2026.103609}
}

RIS

TY  - JOUR
TI  - Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.
AU  - Zalcman G
AU  - Madroszyk A
AU  - Guenzi E
AU  - Dayen C
AU  - Molinier O
AU  - Egenod T
AU  - Poté N
AU  - Debieuvre D
AU  - Beaucaire-Danel S
AU  - Dixmier A
AU  - Pichon E
AU  - Galland-Girodet S
AU  - Giroux-Leprieur E
AU  - Cloarec N
AU  - Cadranel J
AU  - Otto J
AU  - Romand P
AU  - Favier L
AU  - Martinez S
AU  - Mascaux C
AU  - Odier L
AU  - Cortot A
AU  - Audigier-Valette C
AU  - Langlais A
AU  - Amour E
AU  - Morin F
AU  - Antoine M
AU  - Gounant V
AU  - Westeel V
AU  - Toffart AC
PY  - 2026
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2026.103609
UR  - https://doi.org/10.1016/j.jtho.2026.103609
ER  -

APA

G, Z., A, M., E, G., C, D., O, M., T, E., N, P., D, D., S, B., A, D., E, P., S, G., E, G., N, C., J, C., J, O., P, R., L, F., S, M., C, M., L, O., A, C., C, A., A, L., E, A., F, M., M, A., V, G., V, W., & AC, T. (2026). Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2026.103609

Source records

pubmed · retrieved 2026-09-26T01:19:14.631Z